A review of when to start radiation for IDH-mutant gliomas
Original title: Neurology Journal Club: Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is an expert review of an earlier study, not a new result.
The short version
Experts took a second look at a study about the best time to start radiation.
What was studied. This article is an expert review of a 2025 study by Lanman and others. That study looked at people with IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary grade 2 and 3 gliomas. Some had radiation soon after surgery. Others had it put off until later.
What they found. The study found that radiation soon after surgery held off tumor growth for longer. But those patients did not live as long overall. The reviewers point out that this does not match current guidelines. Guidelines advise radiation soon after surgery for people at higher risk.
What this means, and what it doesn't
What it could mean: The best time to start radiation is still an open question. It is fair to ask your care team about timing. They can walk you through the trade-offs for your own case.
What it doesn't mean: This does not mean radiation is wrong, or that anyone should skip it. It is an expert review of one study, not a new result or a new treatment. That study looked back at records that already existed, so it cannot show what caused what. The reviewers say planned studies are still needed. This is not a promise of a cure.
Source: PubMed, October 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.